Drugs / Olmesartan
Olmesartan
Trials 24 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02665832 | Jan → Jun 2016 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT02089399 | May → Jun 2014 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT02955498 | Apr → May 2014 | — | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01823900 | Jan → Feb 2012 | — | Severance Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01831479 | Aug → Sep 2011 | — | Severance Hospital | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03655964 | Aug 2018 → Aug 2019 | ischemic stroke | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| Phase 2 | NCT03024476 | Sep 2016 → Dec 2017 | hypertensive disorder, ischemic stroke | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02516826 | Aug 2015 → Aug 2018 | coronary artery disorder | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01692301 | Dec 2012 → Apr 2015 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT05110898 | Aug 2022 → Aug 2023 | essential hypertension | Brainfarma | Unknown | No outcome recorded |
| Phase 3 | NCT04606563 | Oct 2020 → Apr 2022 | COVID-19 | University of British Columbia | Terminated | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | No outcome recorded |
| Phase 3 | NCT01785472 | Apr 2013 → Aug 2014 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01613209 | Dec 2011 → Sep 2012 | hypertensive disorder | Institute for Pharmacology and Preventive Medicine | Completed | No outcome recorded |
| Phase 3 | NCT00696241 | Jun 2007 → Oct 2008 | essential hypertension | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00098137 | Jan 2005 → May 2009 | paroxysmal atrial fibrillation | Atrial Fibrillation Network | Completed | No outcome recorded |
| Phase 3 | NCT02493322 | ? → Jun 2025 | essential hypertension | EMS | Withdrawn | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT05917275 | Apr 2024 → Oct 2025 | essential hypertension | Radboud University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT06275763 | Oct 2023 → Dec 2025 | hypertensive disorder | National Institute of Cardiology, Warsaw, Poland | Unknown | No outcome recorded |
| Phase 4 | NCT05189015 | Jan 2021 → Jun 2022 | hypertensive disorder, type 2 diabetes mellitus | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02373462 | Aug → Nov 2015 | peripheral arterial disease | Yonsei University | Terminated | No outcome recorded |
| Phase 4 | NCT01713920 | Apr 2010 → Sep 2014 | hypertensive disorder | Sang Hyun Ihm, MD PhD | Completed | No outcome recorded |
| Phase 4 | NCT01089452 | — | hypertensive disorder | Monash University | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00834600 | Dec 2005 → Oct 2011 | hypertensive disorder | The Louis & Rachel Rudin Foundation | Completed | No outcome recorded |
Also used as a comparator or background therapy in 28 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04856969 Comparator | Mar → May 2021 | — | Autotelicbio | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05103332 Background | Nov 2021 → Dec 2023 | essential hypertension | Alnylam Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01870739 Comparator | Oct 2013 → Jun 2015 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00362115 Comparator | May → Dec 2006 | hypertensive disorder | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT00759551 Comparator | Aug 2004 → Jun 2005 | essential hypertension | Takeda | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT06608472 Comparator | Nov 2026 → Apr 2028 expected | essential hypertension | Eurofarma Laboratorios S.A. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04161001 Comparator | Nov 2019 → Nov 2021 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 3 | NCT03009487 Comparator | Jan 2017 → Apr 2018 | hyperlipidemia, hypertensive disorder | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT01876368 Comparator | Sep 2013 → Aug 2014 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01764295 Comparator | Sep 2012 → May 2013 | hyperlipidemia, hypertensive disorder | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT01615198 Comparator | Aug 2012 → Jul 2013 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01599104 Comparator | Jun 2012 → Apr 2013 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00696436 Comparator | Apr 2008 → Aug 2009 | essential hypertension | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT02483936 Comparator | ? → Jun 2025 | essential hypertension | EMS | Withdrawn | No outcome recorded |
| Phase 410 trials | ||||||
| Phase 4 | NCT04394117 Comparator | Jun 2020 → Nov 2021 | COVID-19 | The George Institute | Completed | No outcome recorded |
| Phase 4 | NCT04330300 Comparator | Apr 2020 → Jul 2021 | COVID-19, essential hypertension | National University of Ireland, Galway, Ireland | Suspended | No outcome recorded |
| Phase 4 | NCT04120753 Comparator | Aug 2019 → Jul 2021 | hyperlipidemia, hypertensive disorder | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 4 | NCT04061824 Comparator | May 2016 → Dec 2018 | hyperlipidemia, hypertensive disorder | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT02996916 Comparator | Dec 2015 → Dec 2018 | — | Kurume University | Unknown | No outcome recorded |
| Phase 4 | NCT01377285 Background | Jun 2010 → Dec 2018 | chronic renal failure syndrome | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01101009 Comparator | Apr 2010 → Nov 2012 | hypertensive disorder | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 4 | NCT01271374 Comparator | Apr 2010 → Jun 2011 | hypertensive disorder | InVasc Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 4 | NCT00741585 Comparator | Sep 2008 → Jun 2018 | chronic kidney disease, essential hypertension, stroke disorder | University of Vigo | Completed | No outcome recorded |
| Phase 4 | NCT00295542 Comparator | Mar 2000 → Apr 2009 | hypertensive disorder | University of Vigo | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT03560804 Comparator | Nov 2014 → Sep 2017 | arteriosclerosis disorder | AHEPA University Hospital | Completed | No outcome recorded |
| — | NCT01028534 Comparator | Jul 2010 → Dec 2013 | hypertensive disorder, obstructive sleep apnea syndrome | Kyoto University, Graduate School of Medicine | Completed | No outcome recorded |
| — | NCT00122447 Comparator | May 2005 → May 2011 | glucose intolerance, prediabetes syndrome | Emory University | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Press releases naming this drug 13 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-03-30 | Daiichi Sankyo | Daiichi Sankyo Agrees to Modify the Terms of the Settlement Program for U.S. Olmesartan Products Liability Litigation daiichisankyo.com ↗ |
| 2012-06-11 | Daiichi Sankyo | Daiichi Sankyo Launches Antihypertensive Agent Olmesartan in Mexico daiichisankyo.com ↗ |
| 2010-09-10 | Daiichi Sankyo | APPELLATE COURT AFFIRMS U.S. DISTRICT COURT DECISION IN FAVOR OF DAIICHI SANKYO PATENT FOR BENICAR(R), BENICAR HCT(R), and AZOR(R) daiichisankyo.com ↗ |
| 2010-02-15 | Daiichi Sankyo | FDA Approves Benicar(R) for the Treatment of High Blood Pressure in Children and Adolescents aged 6-16(1) daiichisankyo.com ↗ |
| 2009-12-21 | Daiichi Sankyo | Daiichi Sankyo to Leverage Ranbaxy's Presence in Africa for Marketing and Distribution Olmesartan to be launched in six African countries daiichisankyo.com ↗ |
| 2009-08-03 | Daiichi Sankyo | THE U.S. DISTRICT COURT HAS ISSUED A DECISION IN OUR FAVOR IN OUR U.S. PATENT LITIGATION REGARDING BENICAR(R), BENICAR HCT(R) AND AZOR® daiichisankyo.com ↗ |
| 2008-06-18 | Daiichi Sankyo | New Study Shows Benicar(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering daiichisankyo.com ↗ |
| 2007-10-01 | Daiichi Sankyo | DAIICHI SANKYO EUROPE is applying for approval of its new combination product of Olmesartan and Amlodipin daiichisankyo.com ↗ |
| 2007-05-22 | Daiichi Sankyo | Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007) First Release of Data for New Combination daiichisankyo.com ↗ |
| 2006-11-29 | Daiichi Sankyo | DAIICHI SANKYO, INC. ANNOUNCES FILING OF NEW DRUG APPLICATION FOR AMLODIPINE BESYLATE / OLMESARTAN MEDOXOMIL COMBINATION FOR THE TREATMENT OF HYPERTENSION daiichisankyo.com ↗ |
| 2006-08-02 | Daiichi Sankyo | Sales of Antihypertensive Agent Olmetec® Begin in China daiichisankyo.com ↗ |
| 2006-08-02 | Daiichi Sankyo | SANKYO COMMENCES PATENT LITIGATION AGAINST BENICAR® ANDA FILING IN THE UNITED STATES daiichisankyo.com ↗ |
| 2005-10-12 | Daiichi Sankyo | Completion of the Registration of Trial Subjects for ORIENT on the Suppressive Effects of the Angiotensin II Receptor Blocker Olmetec® against the Progression of Diabetic Nephropathy daiichisankyo.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 56 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | olmesartan | “This is a phase III, non-inferiority, randomized, double-blind, double-dummy, active-controlled, multicenter study to compare the efficacy and safety of N0877 versus double...” NCT06608472 ↗52“The purpose of this study is to assess the pharmacokinetic characteristics of olmesartan and S-amlodipine after single oral administration of Sevikar tab. 10/40mg, a...” NCT02955498 ↗ “Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC)...” NCT06275763 ↗ “The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single-pill combination (SPC) therapy using ambulatory blood pressure monitoring (ABPM) in...” PMID 39504016 ↗ Nov 2024 “One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin,...” NCT04061824 ↗ “Treatment effect of olmesartan to hypertension and rosuvastatin to dyslipidemia is already proven in previous studies, and these medication does not have interaction with each other.” NCT04061824 ↗ “Angiotensin II receptor antagonists ,these medicines have names that end in "sartan".For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan” NCT01377285 ↗ “Single administration of a combination tablet of Rosuvastatin 20mg and Olmesartan 40mg” NCT01823900 ↗ “Candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan” NCT04330300 ↗ “eprosartan, irbesartan, losartan, olmesartan, telmisartan” NCT00684489 ↗ “Olmesartan” NCT02735707 ↗ “Olmesartan” NCT00741585 ↗ |
| Known as | Benicar | “Initially, the participant will be treated with Benicar® (olmesartan) 20mg and Natrilix® (indapamide) 1,5 mg.” NCT05110898 ↗ |
| Known as | OLM | “renin-angiotensin system blockade with the angiotensin II receptor blocker olmesartan (OLM) plus AML” PMID 24293132 ↗ Nov 2013 |
| Known as | Olme | “triple-combination of olmesartan/amlodipine/rosuvastatin (Olme/Amlo/Rosu)” PMID 37814541 ↗ Jan 2023 |
| Known as | olmesartan medoxomil | “To compare this ARB with others in the class, we studied the effects of 2 doses of azilsartan medoxomil, with valsartan 320 mg and olmesartan medoxomil (olmesartan) 40 mg, in a...” PMID 21282560 ↗ Jan 2011 |
| Known as | Olmetec | “co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)” NCT04161001 ↗1“co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).” NCT03009487 ↗ |
| Action | Inhibit | “Blocking the angiotensin (AT) II type 1 receptor (Olmesartan) reduces the incidence of episodes of atrial fibrillation” NCT00098137 ↗ |
| Modality | Other / unclassified | “the ARB olmesartan medoxomil (OLM-M)” PMID 21272195 ↗ Feb 2011 |
| Route | Oral | “Olmesartan tablet, 1 in the morning” NCT00098137 ↗ |